ホーム › 心不全 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける心不全の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、心不全に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
被験者募集中第3相
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
被験者募集中第3相
- Pittsburg, PA Investigative Site 1044, Pittsburgh
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
被験者募集中第2相
- Local Institution - 124, Pittsburgh
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
被験者募集中第2/3相
- Children's Hospital of Pittsburgh ( Site 0010), Pittsburgh
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs
被験者募集中観察研究
- University of Pittsburgh, Pittsburgh
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
被験者募集中観察研究
- Pittsburgh, Pittsburgh
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
被験者募集中観察研究
- University Of Pittsburgh, Pittsburgh
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
被験者募集中第3相
- Tenax Investigational Site, Pittsburgh
Assessment of CCM in HF With Higher Ejection Fraction
被験者募集中
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
- Bryn Mawr Medical Specialists Association, Bryn Mawr · 11マイル先
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
被験者募集中第3相
- UPMC Children's Hospital of Pittsburgh - Cardiology, Pittsburgh
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
被験者募集中
- UPMC, Pittsburgh
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
被験者募集中第3相
- UPMC Children's Hospital of Pittsburgh - Cardiology, Pittsburgh
Quantifying New Heart Muscle Cells
被験者募集中
- Upmc Children'S Hospital of Pittsburgh, Pittsburgh
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
被験者募集中
- Allegheny General Hospital, Pittsburgh
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
被験者募集中
- Allegheny Health Network, Pittsburgh
POCUS-Guided Diuresis for Decompensated Heart Failure
被験者募集中
- UPMC East, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
- UPMC Presbyterian, Pittsburgh
- 他2件
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
被験者募集中第2/3相
- VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh
Left vs Left Randomized Clinical Trial
被験者募集中
- Allegheny-Singer Research Institute, Pittsburgh
- University of Pittsburg, Pittsburgh
Cardiogenic Shock Working Group Registry
被験者募集中観察研究
- Allegheny General Hospital, Pittsburgh
- University Of Pittsburgh Medical Center, Pittsburgh
他の都市における心不全の試験
- New York City, NY51件の研究
- Boston, MA44件の研究
- Dallas, TX42件の研究
- Houston, TX36件の研究
- Cleveland, OH33件の研究
- Chicago, IL31件の研究
- Philadelphia, PA31件の研究
- San Francisco, CA29件の研究
- St. Louis, MO26件の研究
- Durham, NC26件の研究
- Kansas City, MO25件の研究
- Atlanta, GA25件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 肺がん23件の研究
- 前立腺がん23件の研究
- 脳卒中22件の研究
- 頭頸部扁平上皮癌22件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。